New treatment for cancer ‘treats 71% more patients’

By Matthew Vadum, CNN Money Treating patients with an experimental antibody drug known as GevaMed 71% effective at preventing the disease, according to studies published in two science journals. But similar small studies showed…

New treatment for cancer 'treats 71% more patients'

By Matthew Vadum, CNN Money

Treating patients with an experimental antibody drug known as GevaMed 71% effective at preventing the disease, according to studies published in two science journals. But similar small studies showed that using traditional medicine alone was only about half effective at halting the progression of chronic lymphocytic leukemia.

The New England Journal of Medicine reports that GevaMed 71 percent effective as a regimen that combines the antibody with chemotherapy in patients who have failed to respond to first line treatment. There are no approved therapies for patients with chronic lymphocytic leukemia, a cancer of the lymph nodes that usually starts in older patients.

Results for GevaMed 71% effective as a regimen that combines the antibody with chemotherapy in patients who have failed to respond to first line treatment. There are no approved therapies for patients with chronic lymphocytic leukemia, a cancer of the lymph nodes that usually starts in older patients.

The only therapy currently approved to treat chronic lymphocytic leukemia is Livofem, which is given as part of a regimen with chemotherapy, chemotherapy after chemotherapy, and then Livofem once a month for 12 months.

The same articles in The Lancet revealed that patients using GevaMed 71% effective had a 59% success rate, as compared to about 26% for those using traditional medicine alone.

Two groups of patients had the standard treatment: giving just Livofem, and giving GevaMed 71% effective. GevaMed 71% effective also worked in a combination with standard treatment.

It’s important to note that GevaMed 71% effective is much less effective than what it’s supposed to be, and that the initial efficacy was not based on the way the drug was delivered, but on the data it received from clinical trials.

But GevaMed 71% effective is much less effective than what it’s supposed to be, and that the initial efficacy was not based on the way the drug was delivered, but on the data it received from clinical trials.

“GevaMed 71% effective is a large step in the direction of clinical treatments for patients with acute lymphocytic leukemia,” said GevaMed president Roger Cantrell in a press release. “There has been a shift in the pharmaceutical industry towards developing new, and more efficient, treatments for patients with cancer.”

No competitor drugs are available to GevaMed 71% effective. GevaMed is most often tested as a final option for patients who have failed to respond to other treatments.

Acute lymphocytic leukemia is one of about 150 cancer types in the U.S. Those types that are preventable, however, are a small percentage of the large pool of about 200 different types of cancer across the U.S.

Nearly 40,000 people are diagnosed with CLL each year, the National Cancer Institute reports.

Antibodies are good drugs against cancer in general, as long as they work well. Better than this is to find a molecule like CTLA-4 that specifically kills cancer cells.

Leave a Comment